Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.8 USD | -0.46% | +4.74% | +54.40% |
31/05 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
31/05 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
Evolution of the average Target Price on Calliditas Therapeutics AB
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Calliditas Therapeutics AB
Citigroup | |
Stifel Nicolaus | |
HC Wainwright | |
Guggenheim |
EPS Revisions
- Stock Market
- Equities
- CALTX Stock
- CALT Stock
- Consensus Calliditas Therapeutics AB